Silexion Therapeutics Corp. Files Material Definitive Agreement

TL;DR

Silexion Therapeutics (SLXN) signed a major deal on Sept 11, 2025.

AI Summary

Silexion Therapeutics Corp. entered into a material definitive agreement on September 11, 2025. The company, formerly known as Biomotion Sciences, is incorporated in the Cayman Islands and has its principal executive offices in Ramat-Gan, Israel. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing indicates a significant new agreement for Silexion Therapeutics, which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the nature of which is not detailed in this initial filing.

Key Players & Entities

• Silexion Therapeutics Corp (company) — Registrant
• Biomotion Sciences (company) — Former company name
• September 11, 2025 (date) — Date of earliest event reported
• Cayman Islands (jurisdiction) — State or other jurisdiction of incorporation
• Ramat-Gan, Israel (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.0135 — registered Ordinary Shares, par value $0.0135 per share SLXN The Nasdaq Stock Mar
• $1,552.50 — Ordinary Shares at an exercise price of $1,552.50 per share SLXNW The Nasdaq Stock Ma
• $4.00 — e " Warrants "), at a purchase price of $4.00 per Share and accompanying Ordinary War
• $3.9999 — and accompanying Ordinary Warrants, and $3.9999 per Pre-Funded Warrant and accompanying
• $6.0 million — ercises of Warrants) were approximately $6.0 million. The Pre-Funded Warrants are immediate
• $0.0001 — ely exercisable at an exercise price of $0.0001 per Ordinary Share and will not expire
• $25,000 — any also reimbursed the Placement Agent $25,000 for non-accountable expenses and up to
• $100,000 — for non-accountable expenses and up to $100,000 for fees and expenses of legal counsel
• $5.00 — gent Warrants have an exercise price of $5.00 per Ordinary Share (representing 125% o
• $5.2 million — ny from the Offering were approximately $5.2 million before deducting estimated offering exp

Filing Documents

• zk2533780.htm (8-K) — 65KB
• exhibit_4-1.htm (EX-4.1) — 98KB
• exhibit_4-2.htm (EX-4.2) — 99KB
• exhibit_4-3.htm (EX-4.3) — 96KB
• exhibit_4-4.htm (EX-4.4) — 99KB
• exhibit_10-1.htm (EX-10.1) — 200KB
• exhibit_99-1.htm (EX-99.1) — 12KB
• image00001.jpg (GRAPHIC) — 27KB
• 0001178913-25-003309.txt ( ) — 1042KB
• slxn-20250911.xsd (EX-101.SCH) — 5KB
• slxn-20250911_def.xml (EX-101.DEF) — 18KB
• slxn-20250911_lab.xml (EX-101.LAB) — 27KB
• slxn-20250911_pre.xml (EX-101.PRE) — 20KB
• zk2533780_htm.xml (XML) — 6KB

01. Entry Into a Material Definitive Agreement

Item 1.01. Entry Into a Material Definitive Agreement. On September 11, 2025, Silexion Therapeutics Corp (the " Company " or " Silexion ") offered and sold in a public offering on a best efforts basis (the " Offering "), and on September 12, 2025, Silexion consummated the Offering with respect to, (i) 1,392,250 of the Company's ordinary shares (the " Shares "), par value $0.0135 per share (" Ordinary Shares "), (ii) 107,750 pre-funded warrants to purchase up to 107,750 Ordinary Shares (the " Pre-Funded Warrants "), (iii) 1,500,000 Series A ordinary warrants, each to purchase one Ordinary Share (a " Series A Ordinary Warrant ") and (iv) 1,500,000 Series B ordinary warrants, each to purchase one Ordinary Share (a " Series B Ordinary Warrant ", together with the Series A Ordinary Warrants, the " Ordinary Warrants " and together with the Pre-Funded Warrants, the " Warrants "), at a purchase price of $4.00 per Share and accompanying Ordinary Warrants, and $3.9999 per Pre-Funded Warrant and accompanying Ordinary Warrants. Aggregate gross proceeds from the Offering (without taking into account any proceeds from any future exercises of Warrants) were approximately $6.0 million. The Pre-Funded Warrants are immediately exercisable at an exercise price of $0.0001 per Ordinary Share and will not expire until exercised in full. The Series A Ordinary Warrants and Series B Ordinary Warrants have an exercise price of $4.00 per Ordinary Share, are immediately exercisable, and may be exercised until the five (5)-year anniversary and 12-month anniversary, respectively, of the issuance date thereof. A holder of the Warrants will not have the right to exercise any portion of its Pre-Funded Warrants or Ordinary Warrants if the holder (together with such holder's affiliates, and any persons acting as a group together with such holder or any of such holder's affiliates or any other persons whose beneficial ownership of Ordinary Shares would be aggregated with the holder's or any of the

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 4.1 Form of Series A Ordinary Warrant to be sold in the Offering 4.2 Form of Series B Ordinary Warrant to be sold in the Offering 4.3 Form of Pre-Funded Warrant to be sold in the Offering 4.4 Form of Placement Agent Warrant to be issued to the Placement Agent 10.1 Securities Purchase Agreement, dated September 11, 2025, by and between the Company and each investor party thereto 99.1 Press release issued by the Company on September 11, 2025 announcing the pricing of the Offering 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: September 11, 2025 By: /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR